What’s the current market cap for Genus stock?

Genus (GNS) has a market cap of £1.4bn as of June 26, 2026.

What is the P/E ratio for Genus stock?

The price to earnings (P/E) ratio for Genus (GNS) stock is 30.21 as of June 26, 2026.

Does Genus stock pay dividends?

Yes, the Genus (GNS) stock pays dividends to shareholders. As of June 26, 2026, the dividend rate is £0.329 and the yield is 1.54%. Genus has a payout ratio of 44.42% on a trailing twelve-month basis.

When is the next Genus dividend payment date?

The next Genus (GNS) dividend payment date is unconfirmed.

What is the beta indicator for Genus?

Genus (GNS) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Genus stock | £GNS Share Price

07:00

09:10

11:15

13:25

15:30

About Genus

Genus PLC, trading under the ticker GNS on the London Stock Exchange, specializes in animal genetics and biotechnology. The company, founded in 1994 and headquartered in Basingstoke, United Kingdom, operates across multiple countries offering genetically superior pig and cattle breeding stock along with state-of-the-art in vitro fertilization products. Genus PLC aims to empower customers in the livestock sector to enhance the efficiency and profitability of their operations by providing innovative genetic solutions and services.

Ticker

£GNS

Sector

Health

Primary listing

LSE

Employees

3,190

Headquarters

Basingstoke, United Kingdom

Website

www.genusplc.com

Genus Metrics

BasicAdvanced

£1.4bn

30.21

£0.71

0.90

£0.33

1.54%

What the Analysts think about Genus

Analyst ratings (Buy, Hold, Sell) for Genus stock.

Bulls say / Bears say

Genus reported record H1 FY26 financial results, with adjusted operating profit surging 38% to £55.8 million and adjusted profit before tax rising 57% to £55.7 million, driven by robust performance in its PIC division and a £5.6 million milestone payment from its Chinese partner. (Investegate)

Canada’s approval of the PRRS-resistant pig gene edit on 23 January 2026 marks a significant regulatory breakthrough, paving the way for North American commercialization of Genus’s gene-edited PRP line. (Investegate)

Genus’s Value Acceleration Programme Phase 3 has been actioned and is on track to deliver approximately £7 million of in-year benefit and £9 million of annualized benefit, underpinning margin expansion in its bovine segment. (Investegate)

The post-period deconsolidation of the Chinese porcine joint venture will reduce reported group revenues and earnings comparability, as PIC China shifts to equity accounting following the 31 January 2026 JV formation. (Investegate)

Volumes in the ABS segment saw conventional dairy and beef volumes decline 2% year-on-year, signaling potential headwinds in the bovine genetics market despite sexed volume growth. (Investegate)

Free cash flow decreased 20% to £8.2 million and cash generated by operations fell 16% to £38.5 million in H1 FY26, driven by a £22.7 million working capital outflow, raising concerns about cash conversion under its growth initiatives. (Investegate)

Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2026.

Genus Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Genus Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by London Stock Exchange, through Infront.

Bulls say / Bears say

Volumes in the ABS segment saw conventional dairy and beef volumes decline 2% year-on-year, signaling potential headwinds in the bovine genetics market despite sexed volume growth. (Investegate)

Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2026.

About Genus

Ticker

Primary listing

Employees

Genus Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Genus

Analyst Ratings

Bulls say / Bears say

Genus Financial Performance

Income Statement

Genus Earnings Performance

Earnings per share (EPS)

Buy £GNS

Lightyear

Legal

Work with us

Bulls say / Bears say

Genus/£GNS

About Genus

Ticker

Primary listing

Employees

Genus Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Genus

Analyst Ratings

Bulls say / Bears say

Genus Financial Performance

Income Statement

Genus Earnings Performance

Earnings per share (EPS)

What’s the current market cap for Genus stock?

What is the P/E ratio for Genus stock?

Does Genus stock pay dividends?

When is the next Genus dividend payment date?

What is the beta indicator for Genus?

Bulls say / Bears say